- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00469612
Evaluating NeuroVision's Neural Vision Correction (NVC) Myopia Treatment
Evaluating the Efficacy of NeuroVisions's NVC Treatment for Low Myopia
The purpose of the present study is to carry out a trial to evaluate the clinical efficacy of the NeuroVision Low Myopia Treatment.
The specific questions to be answered are:
- Is there an improvement in vision following the treatment without bringing about a change in the subject's prescription for glasses?
- Can any treatment effect be seen at 6 months and 12 months after the termination of the treatment?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Myopia and its treatment modalities are one of the widely studied areas in vision research. So far all the treatment options have been optical i.e., patients with myopia are either corrected with spectacles, contact lenses or refractive surgery to provide clear vision. NeuroVision's NVC vision correction technology will be a novel method in the treatment of low myopia as the technology is directed at specific neuronal interactions at the level of the visual cortex (area responsible for vision in the brain). It uses a non-invasive, patient-specific treatment that purports to improve neuronal efficiency and induce improvement in the overall ability to see due to a reduction in noise and increase in signal strength. As visual perception quality depends both on the input received through the eye and the processing in the visual cortex, NeuroVision's technology is hypothesized to compensate for blurred (myopic) inputs, by enhancing neural processing.
We will conduct a clinical evaluation of the effectiveness of this system. The subject will be exposed to a set of visual stimulations (pattern with black and white lines) and visual threshold level will be obtained. The subject will look at these patterns on a computer. The treatment will be applied in successive 30-40 minute sessions, administered 2-3 times a week, for a total of 40 sessions. Every 5 sessions, subject's visual performance (visual acuity, ability to see letters of varying size, and CSF, ability to see black and white lines of varying contrast) will be tested in order to continuously monitor a subject's progress. At the end of a session, the data will be sent to the NeuroVision Web Server. Proprietary algorithmic software will analyze the patient's performance and progress and will generate the parameters for the next treatment session. The purpose of the study is to assess the effect on corrected or uncorrected visual performance following treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- College of Optometry, The Ohio State University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age should be between 18 to 59 years
- Spherical equivalent in the worst eye should not exceed -1.5 DS and the astigmatism should not exceed -0.75 DC.
- The subject's refractive status is stable, with no increase beyond 0.5D in sphere or cylinder over the last six months. That is, the subject's spectacle prescription should not differ from the auto-refraction value by 0.50D.
- Unaided visual acuity is 0.6 LogMAR or better in the eye with the poorer unaided acuity
- Unaided visual acuity is 0.1 LogMAR or worse in the eye with better unaided acuity
- Unaided visual acuity difference between both eyes is less than 0.3 LogMAR
- Best-corrected visual acuity is 0.04 LogMAR or better in both eyes.
The subject should be aware that the study has the following features:
- The recommended pace for the treatment sessions is at least 3 sessions per week.
- Interruptions should not be longer than 2 weeks during the treatment course. Note: The subject is free to voluntarily withdraw from the study at any time.
Exclusion Criteria:
- The subject suffers from any other visually disabling eye disease(s) or other causes for the reduced visual acuity, aside from myopia and/or astigmatism
- The subject suffers from myopia-related visual complications resulting in visual loss, including myopic macular degeneration, myopic cataract and previous or pre-existing myopic retinal detachment.
- The subject is suffering from Diabetes Mellitus.
- The subject suffers from Migraines
- The subject suffers from Epilepsy
- The subject is pregnant. (It is not recommended to include pregnant women because of the expected visual fluctuations. The NV treatment , basically using a computer, has no impact on the pregnancy.) No pregnancy testing will be done but will be identified through verbal history. The study has use of tropicamide drug (dilation drops) and proparacaine (topical anesthetic), which are a routinely used eye drop in everyday clinical practice and no adverse effects have been reported so far on pregnant women or fetus.
- The subject has an activity limitation due to medical disorders (including migraines, seizure disorders, etc.), medications, or emotional status that might potentially impair the subject's ability to perform the treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
NeuroVision's NVC treatment for low myopia
|
NeuroVision's NVC vision correction technology is a method in the treatment of low myopia as the technology is directed at specific neuronal interactions at the level of the visual cortex (area responsible for vision in the brain). The subject will be exposed to a set of visual stimulations (pattern with black and white lines) and visual threshold level will be obtained. The subject will look at these patterns on a computer. The treatment will be applied in successive 30-40 minute sessions, administered 2-3 times a week, for a total of 40 sessions. Every 5 sessions, subject's visual performance (visual acuity and CSF) will be tested in order to continuously monitor a subject's progress. |
No Intervention: B
The subjects in this group will serve as controls and will be the no intervention group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Visual Acuity
Time Frame: Every 5th visit
|
Every 5th visit
|
Contrast Sensitivity Function
Time Frame: Every 5th visit
|
Every 5th visit
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Refractive Error
Time Frame: Every 10th visit
|
Every 10th visit
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Polat U, Sagi D. Spatial interactions in human vision: from near to far via experience-dependent cascades of connections. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1206-9. doi: 10.1073/pnas.91.4.1206.
- Polat U, Sagi D. Lateral interactions between spatial channels: suppression and facilitation revealed by lateral masking experiments. Vision Res. 1993 May;33(7):993-9. doi: 10.1016/0042-6989(93)90081-7.
- Polat U, Sagi D. The architecture of perceptual spatial interactions. Vision Res. 1994 Jan;34(1):73-8. doi: 10.1016/0042-6989(94)90258-5.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2006H0045
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myopia
-
He Eye HospitalNot yet recruiting
-
University of BradfordCoopervision, Inc.; University of HuddersfieldNot yet recruiting
-
Visioneering Technologies, IncRecruitingMyopiaUnited States, Canada, Hong Kong, Singapore
-
University Eye Hospital, FreiburgRecruiting
-
Shanghai 10th People's HospitalCompletedMyopia | Myopia, ProgressiveChina
-
Tianjin Eye HospitalActive, not recruiting
-
Tianjin Eye HospitalCompleted
-
Sultan Qaboos UniversityChristian Medical College, Vellore, IndiaUnknown
-
Peking University People's HospitalUnknownProgressive MyopiaChina
-
Shanghai Eye Disease Prevention and Treatment CenterNot yet recruiting
Clinical Trials on NeuroVision's NVC treatment for Low Myopia
-
Beijing Airdoc Technology Co., Ltd.Eye & ENT Hospital of Fudan UniversityRecruiting
-
Beijing Airdoc Technology Co., Ltd.The First People's Hospital of XuzhouRecruiting
-
Beijing Airdoc Technology Co., Ltd.CompletedMyopia | Amblyopia | Ametropia | Refractive Error - Myopia AxialChina
-
National Center for Complementary and Integrative...Completed
-
University of VirginiaDIREX SYSTEMS CORPORATIONWithdrawnVasculogenic Erectile Dysfunction
-
University of MiamiDIREX SYSTEMS CORPORATIONCompletedVasculogenic Erectile DysfunctionUnited States
-
Winthrop UniversityRecruiting
-
Bispebjerg HospitalUniversity Hospital Bispebjerg and Frederiksberg; Cambridge Weight Plan LimitedCompletedAngina Pectoris | Coronary Microvascular DiseaseDenmark
-
Assistance Publique - Hôpitaux de ParisCompletedLung Cancer | Non Small Cell Lung CancerFrance
-
University of OsloCompleted